Skip to main content

Table 1 Baseline characteristics of patients with an eGFR of less than 30 mL/min/1.73m2

From: Propensity score matched analysis for the safety and effectiveness of remdesivir in COVID-19 patients with renal impairment

 

Unmatched cohort

Propensity score-matched cohort

Remdesivir

(N = 229)

Standard care

(N = 335)

P value

Remdesivir

(N = 178)

Standard care

(N = 178)

P value

Age (year), median (IQR)

76 (66–83)

73 (60–83)

0.026

75 (66–83)

74 (63.8–84)

0.405

Male, N (%)

75 (32.8)

147 (43.9)

0.009

54 (30.3)

64 (36.0)

0.260

BMI (kg/m2), median (IQR)

23.3 (20.8–26.4)

22.8 (20.4–25.5)

0.205

23.3 (20.8–26.4)

23 (20.2–24.9)

0.242

Underlying disease, N (%)

 Hypertension

194 (84.7)

256 (76.4)

0.016

152 (85.4)

139 (78.1)

0.075

 Diabetes mellitus

142 (62.0)

170 (50.7)

0.008

112 (62.9)

105(59.0)

0.447

 Congestive heart disease

19 (8.3)

40 (11.9)

0.165

15 (8.4)

24 (13.5)

0.127

 Cerebrovascular accident

42 (18.3)

41 (12.2)

0.045

36 (20.2)

28 (15.7)

0.270

 Chronic liver disease

14 (6.1)

15 (4.5)

0.388

13 (7.3)

10 (5.6)

0.518

 Solid cancer

30 (13.1)

33 (9.9)

0.229

22 (12.4)

16 (9.0)

0.303

 Hematologic malignancy

3 (1.3)

1 (0.3)

0.309

1 (0.6)

1 (0.6)

0.999

 ESRD (iHD or PD)

70 (30.6)

109 (32.5)

0.622

61 (34.3)

52 (29.2)

0.305

 Kidney transplantation

8 (3.5)

15 (4.5)

0.562

5 (2.8)

7 (3.9)

0.557

 Immunosuppressant use, N (%)

12 (5.2)

18 (5.4)

0.945

8 (4.5)

10 (5.6)

0.629

 Charlson Comorbidity Index, score, median (IQR)

7 (5–8)

6 (4–8)

0.012

7 (5–8)

7 (5–8)

0.431

Baseline severity

 NEWS-2 score at admission, median (IQR)

5 (2–8)

1 (0–4)

 < 0.001

5 (2–8)

2 (1–5)

 < 0.001

 Disease severity scores, median (IQR)

3 (2–3)

2 (1–2)

 < 0.001

3 (1.8–3)

2 (1–3)

 < 0.001

 Pneumonia, N (%)

172/225 (76.4)

169/324 (52.2)

 < 0.001

137 (77)

100 (56.2)

 < 0.001

 Remdesivir 5-day course indicationa

211 (92.1)

206 (61.5)

 < 0.001

161 (90.4)

123 (69.1)

 < 0.001

 Steroid use for treatmentb

171 (74.7)

83 (24.8)

 < 0.001

85 (47.8)

81 (45.5)

0.671

 Oxygen requirement, N (%)

127 (55.5)

71 (21.2)

 < 0.001

100 (56.2)

47 (26.4)

 < 0.001

 No oxygen requirement

102 (44.5)

264 (78.8)

 < 0.001

78 (43.8)

131 (73.6)

 < 0.001

 Nasal cannula

102 (44.5)

46 (13.7)

 

81 (45.5)

33 (18.5)

 

 Facial mask

11 (4.8)

10 (3.0)

 

7 (3.9)

6 (3.4)

 

 High flow nasal cannula

8 (3.5)

11 (3.3)

 

7 (3.9)

5 (2.8)

 

 Invasive ventilation

6 (2.6)

4 (1.2)

 

5 (2.8)

3 (1.7)

 

 ECMO

0 (0)

0 (0)

 

0 (0)

0 (0)

 

Initial laboratory result, median (IQR)

 Creatinine (mg/dL)

3.2 (2.4–6.7)

3.6 (2.5–7.8)

0.168

3.5 (2–8)

3 (3–7)

0.631

 AST (IU/L)

34 (22–53)

24 (17–35)

 < 0.001

32.5 (21–51)

24 (17–37)

 < 0.001

 ALT (IU/L)

17 (12–27)

15 (11–22)

0.006

17 (12–27)

16 (11–22.3)

0.089

 eGFR (mL/min/1.73m2)

18 (8–24)

15 (6–23)

0.058

16 (7–23.3)

16.5 (7–23)

0.822

  1. Abbreviations: eGFR estimated glomerular filtration rate, IQR interquartile range, BMI body mass index (weight in kilograms divided by height in meters squared), ESRD end-stage renal disease, iHD intermittent hemodialysis, PD peritoneal dialysis, NEWS-2 National Early Warning Score-2, ECMO extracorporeal membrane oxygenation, AST aspartate aminotransferase, ALT alanine aminotransferase
  2. aIndications: (1) oxygen saturation of less than or equal to 94% for room air, (2) requirement for oxygen supplementation, or (3) chest imaging suggestive of viral pneumonia
  3. bSteroid use for COVID-19 treatment
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us